Increased CD154 expression in uninfected infants born to HIV-positive mothers exposed to antiretroviral prophylaxis

Viral Immunology

Volumn 19, Issue 3, 2006, Pages 363-372

  Romano, Maria Fiammetta ^a   Buffolano, Wilma ^a   Bisogni, Rita ^a   Russo, Rosario ^a   Liuzzi, Raffaele ^b   Bunders, Madeleine ^c   Newell, Marie Louise ^c   Giarrusso, Patrizia Carandente ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD40 LIGAND; SPIRAMYCIN; ZIDOVUDINE;

ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFANT; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTNATAL CARE; PRENATAL CARE; T LYMPHOCYTE ACTIVATION; TOXOPLASMOSIS; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA, VIRAL; VIRAL LOAD;

EID: 33750941974     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.363     Document Type: Conference Paper

References (37)

1. Pozniak A: Optimizing efficacy and tolerability in today's HAART [review]. AIDS Reader 2003;S4-S8.
2. Katz A: The evolving art of caring for pregnant women with HIV infection. J Obst Gynecol Neonatal Nurs 2003;32:102-108.
3. Moodley D, Moodley J, Coovadia H, et al.; South African Intrapartum Nevapirine Trial (SAINT) investigators: A multicenter randomized controlled trial of nevapirine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:721-724.
4. + T cells in vivo. Clin Exp Immunol 2002;130:293-299.
5. Braun M and Vierling JM: The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transpl 2003;9:S79-S89.
6. + T-cell counts. Clin Diagn Lab Immunol 2002;9:558-561.
7. Clark LB and Foy TM: CD40 and its ligand. Adv Immunol 1996;63:43-78.
8. Grewal IS and Flavell SA: CD40 and CD154 in cell mediated immunity. Annu Rev Immunol 1998;16:111-135.
9. Lane P, Traunecker A, Hubele S, et al.: Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur J Immunol 1992;22:2573-2578.
10. Larder LL, O'Fallon S, Somoza C, et al.: CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995;154:97-105.
11. Bachmann MF and Kopf M: Balancing protective immunity and immunopathology. Curr Opin Immunol 2002;14:413-419.
12. Kuwana M, Kawakami Y, and Ikeda Y: Suppression of autoreactive T-cell response to glycoprotein Iib-IIIia by blockade of CD40/CD154 interaction: Implications for treatment of immune thrombocytopenic purpura. Blood 2003;101:621-623.
13. Racke MK and Stuart RW: Targeting T cell costimulation in autoimmune disease. Expert Opin Ther Targets 2002;6:275-289.
14. Loken, MR, Brosnan JM, Bach BA, and Ault KA: Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. Cytometry 1990;11:453-459.
15. Centers for Disease Control and Prevention; Health Resources and Services Administration, National Institutes of Health; and HIV Medicine Association of the Infectious Diseases Society of America: Incorporating HIV prevention into the medical care of persons living with HIV: Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003;52:1-24.
16. Erratum in: MMWR Recomm Rep 2004;53:744.
17. Coll O, Fiore S, Floridia M, et al.: Pregnancy and HIV infection: A European consensus on management [review]. AIDS 2002;16(Suppl 2):S1-S18.
18. Landreau-Mascaro A, Barret B, Mayaux MJ, et al.: Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002;359:583-584.
19. Van Kooten C and Bancherau J: CD40-CD40 ligand: A multifunctional receptor-ligand pair. Adv Immunol 1996;61:1-77.
20. + T-cell enumeration. Cytometry 2002;50:69-77.
21. + T-cell counting by flow cytometry: CD45 gating for volumetric analysis. Clin Diagn Lab Immunol 2002;9:1085-1094.
22. Kwekkeboom J, De Boer M, Tager JM, et al.: CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells. Immunology 1993;79:439-444.
23. + T lymphocytes of systemic sclerosis patients. J Autoimmun 2000;15:61-66.
24. European Collaborative Study: Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458-465.
25. Bellòn Cano JM, Sànchez-Ramòn S, Ciria L, et al.: The effects on infants of potent antiretroviral therapy during pregnancy: A report from Spain. Med Sci Monit 2004;10:179-184.
26. Thorne C and Newell ML: The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf 2005;4:323-335.
27. Lipshultz SE, Easley KA, Orav EJ, et al.: Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 2000;343:759-766.
28. Zareba KM, Lavigne JE, and Lipshultz SE: Cardiovascular effects of HAART in infants and children of HIV-infected mothers. Cardiovasc Toxicol 2004;4:271-279.
29. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al.: Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003;17:2053-2061.
30. Bunders M, Thorne C, and Newell ML: Maternal and infant factors and lymphocyte CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers. AIDS 2005;19:1071-1079.
31. Newell ML and Rogers M: Pregnancy and HIV infection: A European consensus on management. AIDS 2002;16 (Suppl 2).
32. Clerici M, Sarasella M, Colombo F, et al.: T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood 2000;96:3866-3871.
33. Elliott SR, Roberton DM, Zola H, et al.: Expression of the costimulator molecules, CD40 and CD154, on lymphocytes from neonates and young children. Hum Immunol 2000;61:378-388.
34. Hamilton BJ, Genin A, Cron RQ, et al.: Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression. Mol Cell Biol 2003;23:510-525.
35. Kornbluth RS: The emerging role of CD40 ligand in HIV infection. J Leukoc Biol 2000;68:373-382.
36. Nepom GT and Erlich H: MHC class-II molecules and autoimmunity. Annu Rev Immunol 1991;9:493-525.
37. Shevach EM: Regulatory T cells in autoimmunity. Annu Rev Immunol 2000;18:423-449.